Medisun Forms China Stem Cell JV with Belgium's Cardio3

Medisun International, a Hong Kong startup that plans to develop a portfolio of regenerative treatments for China, formed a JV with Cardio3 BioSciences of Belgium. The JV will hold China rights to Cardio3’s stem cell treatment, C-Cure®. A clinical-stage product for congestive heart failure, C-Cure is based on stem cells that are guided toward becoming heart cells. Medisun will make a $38 million investment in Cardio3, giving it an 8% stake in the company. In addition, Medisun has committed at least $27 million to the China joint venture. More details.... Stock Symbols: (PA: CARD; BX: CARD) Share this with colleagues: // //